The clinical trial, sponsored by the University of Miami, focuses on long-term follow-up and maintenance therapy with thalidomide (THALOMID) for patients with Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma. The completion of this trial may provide valuable data on the efficacy and safety of thalidomide in a maintenance setting, which could enhance its market positioning against competing therapies. Given the limited patient enrollment (2 participants), the commercial impact may be constrained unless further studies are initiated. The results could influence treatment guidelines and reimbursement strategies, particularly in the context of supportive care for lymphoma patients. The trial's completion and subsequent data release will be critical for stakeholders assessing thalidomide's ongoing role in oncology.